西南国防医药
西南國防醫藥
서남국방의약
MEDICAL JOURNAL OF NATIONAL DEFENDING FORCES IN SOUTHWEST CHINA
2015年
6期
600-602
,共3页
肝动脉化疗栓塞%恩替卡韦%艾迪注射液%乙肝%肝癌%HBV DNA%AFP
肝動脈化療栓塞%恩替卡韋%艾迪註射液%乙肝%肝癌%HBV DNA%AFP
간동맥화료전새%은체잡위%애적주사액%을간%간암%HBV DNA%AFP
TACE%entecavir%AD injection%hepatitis B%liver cancer%HBV DNA%AFP
比较肝动脉化疗栓塞(TACE)联合艾迪注射液与恩替卡韦降低乙肝合并肝癌患者甲胎蛋白(AFP)水平及对HBV DNA转阴率的影响。以2010年6月~2011年11月在我科室治疗的70例乙肝合并肝癌患者作为研究对象，随机分为恩替卡韦组和艾迪组，两组均联合TACE治疗。观察比较两组治疗后不同时间HBV DNA和AFP改变。恩替卡韦组总有效率(77.14%)与艾迪组(85.71%)比较无统计学差异(>0.05)；艾迪组TACE术后4~48 w的AFP均显著低于恩替卡韦组(<0.05)；除术后第1年两组HBV DNA转阴率无显著差异(>0.05)外，第2、3年恩替卡韦组HBV DNA转阴率分别为57.14%、71.43%，均显著低于艾迪组的80.00%和91.43%(<0.05)。艾迪注射液与恩替卡韦治疗乙肝合并肝癌均有显著疗效，比较而言，艾迪注射液可显著降低AFP水平，提高HBV DNA转阴率，故应将TACE联合艾迪注射液作为首选方案。
比較肝動脈化療栓塞(TACE)聯閤艾迪註射液與恩替卡韋降低乙肝閤併肝癌患者甲胎蛋白(AFP)水平及對HBV DNA轉陰率的影響。以2010年6月~2011年11月在我科室治療的70例乙肝閤併肝癌患者作為研究對象，隨機分為恩替卡韋組和艾迪組，兩組均聯閤TACE治療。觀察比較兩組治療後不同時間HBV DNA和AFP改變。恩替卡韋組總有效率(77.14%)與艾迪組(85.71%)比較無統計學差異(>0.05)；艾迪組TACE術後4~48 w的AFP均顯著低于恩替卡韋組(<0.05)；除術後第1年兩組HBV DNA轉陰率無顯著差異(>0.05)外，第2、3年恩替卡韋組HBV DNA轉陰率分彆為57.14%、71.43%，均顯著低于艾迪組的80.00%和91.43%(<0.05)。艾迪註射液與恩替卡韋治療乙肝閤併肝癌均有顯著療效，比較而言，艾迪註射液可顯著降低AFP水平，提高HBV DNA轉陰率，故應將TACE聯閤艾迪註射液作為首選方案。
비교간동맥화료전새(TACE)연합애적주사액여은체잡위강저을간합병간암환자갑태단백(AFP)수평급대HBV DNA전음솔적영향。이2010년6월~2011년11월재아과실치료적70례을간합병간암환자작위연구대상，수궤분위은체잡위조화애적조，량조균연합TACE치료。관찰비교량조치료후불동시간HBV DNA화AFP개변。은체잡위조총유효솔(77.14%)여애적조(85.71%)비교무통계학차이(>0.05)；애적조TACE술후4~48 w적AFP균현저저우은체잡위조(<0.05)；제술후제1년량조HBV DNA전음솔무현저차이(>0.05)외，제2、3년은체잡위조HBV DNA전음솔분별위57.14%、71.43%，균현저저우애적조적80.00%화91.43%(<0.05)。애적주사액여은체잡위치료을간합병간암균유현저료효，비교이언，애적주사액가현저강저AFP수평，제고HBV DNA전음솔，고응장TACE연합애적주사액작위수선방안。
To compare the effects of transarterial chemoembolization (TACE) combined with Aidi (AD) injection or entecavir on reduction of AFP levels of hepatitis B (HVB) patients complicated with liver cancer and study the impacts on negative conversion ratio of HBV DNA. Total 70 HVB patients complicated with liver cancers to receive treatment in our department from June 2010 to November 2011 were taken as the study subjects and randomly divided into entecavir group and AD group. The two groups received TACE combination therapy. The changes of HBV DNA and AFP in the two groups in different postoperative times were observed. The overall efficacy in entecavir group (77.14%) and AD group (85.71%) had no statistic difference ( >0.05). In 4-48 weeks after the operation, AFP in AD group was obviously lower than that in entecavir group ( <0.05). In the 1st year after the operation, the negative conversion ratios of HBV DNA in the two groups had no obvious difference ( >0.05), but in the 2nd and 3rd year, the negative conversion ratio of HBV DNA in entecavir group was 57.14%and 71.43%, respectively, lower than that in AD group ( 80.00%and 91.43%)( <0.05). Both AD injection and entecavir can achieve a significant curative effect in treatment of HVB complicated with liver cancer. Comparatively, AD injection can significantly reduce AFP level and increase the negative conversion ratio of HBV DNA. So TACE combined with AD injection should be taken as the preferred option.
